Medical journal of the Islamic Republic of Iran · 2025
The Impact of Intraoperative Dexmedetomidine Infusion on Postoperative Delirium Prevention in Intensive Care Unit Patients after Esophagectomy: A Randomized Double-Blind Clinical Trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mohammadipour Anvari Hassan, Shiri Hossein, Charsouei Saeid, Ashrafi Nima, Rezaei Mansour
Аннотация
BACKGROUND: Delirium is a significant issue for esophagectomy patients, with dexmedetomidine (Dex) showing promise in alleviating this burden. A randomized trial on Dex's role in post-esophagectomy delirium can enhance care strategies and patient outcomes.
METHODS: This randomized, double-blind clinical trial, conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, in Iran in 2022, involved 60 esophagectomy patients. The intervention group received Dex infusion (0.5 μg/kg/h), while the control group received normal saline. Postoperatively, patients received analgesia and were monitored for delirium incidence over 3 days in the intensive care unit (ICU) using the Confusion Assessment Method. This study utilized an independent-sample t test, the Mann-Whitney U test, the χ2 test, and the Kaplan-Meier survival analysis with a log-rank test for data comparisons.
RESULTS: Delirium in the ICU over 3 days after surgery was significantly lower in the intervention group (10%, n=3) compared with the control group (20%, n=6) (relative risk, 0.62 [95% CI, 0.42-0.98]; P=0.036). On the first day, no delirium cases occurred in the intervention group, contrasting with 2 cases in the control group (P=0.014). Similarly, on the second day, one case was observed in the intervention group versus 2 in the control group (P=0.042). On the third day, 2 cases were recorded in the intervention group versus 3 in the control group (P=0.031).
CONCLUSION: The significant reduction in delirium occurrence observed in patients receiving intraoperative Dex infusion highlights its potential as a preventive strategy for postoperative delirium in ICU patients after esophagectomy.
METHODS: This randomized, double-blind clinical trial, conducted at Imam Reza Hospital, Tabriz University of Medical Sciences, in Iran in 2022, involved 60 esophagectomy patients. The intervention group received Dex infusion (0.5 μg/kg/h), while the control group received normal saline. Postoperatively, patients received analgesia and were monitored for delirium incidence over 3 days in the intensive care unit (ICU) using the Confusion Assessment Method. This study utilized an independent-sample t test, the Mann-Whitney U test, the χ2 test, and the Kaplan-Meier survival analysis with a log-rank test for data comparisons.
RESULTS: Delirium in the ICU over 3 days after surgery was significantly lower in the intervention group (10%, n=3) compared with the control group (20%, n=6) (relative risk, 0.62 [95% CI, 0.42-0.98]; P=0.036). On the first day, no delirium cases occurred in the intervention group, contrasting with 2 cases in the control group (P=0.014). Similarly, on the second day, one case was observed in the intervention group versus 2 in the control group (P=0.042). On the third day, 2 cases were recorded in the intervention group versus 3 in the control group (P=0.031).
CONCLUSION: The significant reduction in delirium occurrence observed in patients receiving intraoperative Dex infusion highlights its potential as a preventive strategy for postoperative delirium in ICU patients after esophagectomy.